Having trouble accessing articles? Reset your cache.

Reata’s pivotal data in Friedreich ataxia point to submissions

Days after regaining worldwide rights to omaveloxolone, Reata announced plans to submit regulatory applications in the U.S. and other territories for the compound in Friedreich ataxia based on newly released pivotal trial data.

Reata Pharmaceuticals

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers